Trial Profile
Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in Patients With BRAF-Mutant Melanoma and Other Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Onalespib (Primary) ; Trametinib (Primary)
- Indications Colon cancer; Malignant melanoma; Solid tumours
- Focus Adverse reactions
- 31 May 2020 Results (n=22) determine the safety and efficacy of AT13387, in combination with dabrafenib and trametinib in patients with solid tumors,presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 15 Jan 2019 Planned primary completion date changed from 30 Jun 2018 to 31 Mar 2019.
- 15 Jan 2019 Status changed from recruiting to active, no longer recruiting.